AbbVie - ABBV Stock Forecast, Price & News

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

AbbVie Stock Performance

NYSE:ABBV opened at $142.29 on Tuesday. The company has a market capitalization of $251.58 billion, a PE ratio of 20.15, a P/E/G ratio of 4.00 and a beta of 0.70. The company has a debt-to-equity ratio of 4.15, a quick ratio of 0.75 and a current ratio of 0.84. AbbVie has a fifty-two week low of $105.56 and a fifty-two week high of $175.91. The company has a 50 day simple moving average of $146.81 and a two-hundred day simple moving average of $150.59.

AbbVie (NYSE:ABBV - Get Rating) last issued its earnings results on Friday, July 29th. The company reported $3.51 EPS for the quarter, beating the consensus estimate of $3.42 by $0.09. The company had revenue of $14.58 billion during the quarter, compared to the consensus estimate of $14.64 billion. AbbVie had a return on equity of 158.41% and a net margin of 22.03%. The firm's revenue for the quarter was up 4.5% compared to the same quarter last year. During the same period last year, the business posted $3.11 EPS. Research analysts anticipate that AbbVie will post 14.05 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Monday, August 15th. Stockholders of record on Friday, July 15th were issued a dividend of $1.41 per share. This represents a $5.64 dividend on an annualized basis and a dividend yield of 3.96%. The ex-dividend date of this dividend was Thursday, July 14th. AbbVie's payout ratio is 79.89%.

Analyst Ratings Changes

Several research analysts have commented on ABBV shares. Atlantic Securities decreased their price objective on shares of AbbVie from $178.00 to $162.00 and set a "neutral" rating for the company in a report on Monday, August 1st. UBS Group reduced their target price on shares of AbbVie from $154.00 to $146.00 and set a "neutral" rating for the company in a report on Monday, August 1st. Morgan Stanley cut their price target on shares of AbbVie from $191.00 to $188.00 and set an "overweight" rating on the stock in a report on Monday, August 1st. SVB Leerink assumed coverage on AbbVie in a research report on Monday, May 23rd. They issued an "underperform" rating and a $140.00 price target for the company. Finally, Piper Sandler dropped their target price on AbbVie from $160.00 to $155.00 in a research report on Friday, July 29th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, AbbVie has an average rating of "Moderate Buy" and an average price target of $159.63.

Insider Activity

In related news, Vice Chairman Michael Severino sold 79,801 shares of the firm's stock in a transaction on Monday, May 23rd. The shares were sold at an average price of $150.90, for a total transaction of $12,041,970.90. Following the completion of the transaction, the insider now directly owns 152,103 shares of the company's stock, valued at $22,952,342.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 0.08% of the company's stock.